About Transmembrane and immunoglobulin domain-containing protein 2
Transmembrane and immunoglobulin domain-containing protein 2 (TMIGD2) is a protein
from Homo sapiens identified by UniProt accession
Q96BF3, 282 residues long.
MolForge cross-references it against 0 known binders and
44 disease associations.
Target properties
| Protein name | Transmembrane and immunoglobulin domain-containing protein 2 |
|---|
| UniProt accession | Q96BF3 |
|---|
| Gene | TMIGD2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 282 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (44)
Diseases linked to this target (Open Targets).
- neoplasm · score 0.09
- oral squamous cell carcinoma · score 0.08
- acute myeloid leukemia · score 0.07
- colorectal carcinoma · score 0.07
- cutaneous melanoma · score 0.05
- vital capacity · score 0.05
- response to bronchodilator · score 0.05
- gonorrhea · score 0.04
- non-small cell lung carcinoma · score 0.04
- dysplasia · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q96BF3-F1 | alphafold | PREDICTED | 68.89 | — |
Amino-acid sequence (282 residues)
MGSPGMVLGL LVQIWALQEA SSLSVQQGPN LLQVRQGSQA TLVCQVDQAT AWERLRVKWT KDGAILCQPY ITNGSLSLGV CGPQGRLSWQ APSHLTLQLD PVSLNHSGAY VCWAAVEIPE LEEAEGNITR LFVDPDDPTQ NRNRIASFPG FLFVLLGVGS MGVAAIVWGA WFWGRRSCQQ RDSGNSPGNA FYSNVLYRPR GAPKKSEDCS GEGKDQRGQS IYSTSFPQPA PRQPHLASRP CPSPRPCPSP RPGHPVSMVR VSPRPSPTQQ PRPKGFPKVG EE
Explore Transmembrane and immunoglobulin domain-containing protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets